ORPHA:418959
Squamous cell carcinoma of the stomach
Also known as: Gastric squamous cell carcinoma
Publications
1,035
Trials
5
Interventional, condition-specific
Researchers
1,188
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare epithelial tumour of stomach, defined histopathologically as keratinizing cell masses with pearl formation, mosaic pattern of cell arrangement, intercellular bridges, and high concentrations of sulphydryl or disulphide bonds, arising directly from gastric mucosa, without esophageal involvement. It is characterized by preferential location in the upper third of the stomach, high probability of lymphovascular and serosal invasion and late onset of clinical symptoms associated with poor prognosis including nonspecific symptoms of abdominal pain, dysphagia, vomiting, melena or hematochezia, haematemesis and weight loss.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006230
- UMLS:C1333789
- NCIT:C5475
Additional Mondo synonyms (5)
gastric (stomach) squamous cell cancer · gastric squamous cell carcinoma · squamous cell carcinoma of stomach · squamous cell carcinoma of the stomach · stomach squamous cell carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,035 matched papers (721 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
5 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,035
1,035 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,035 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
721 in the last 10 years · low confidence
Phrase hits: 1,035 · MeSH hits: 0
Who's working on it?
1,188
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang X11 papers · 2026
Department of Pathology, Basic Medicine College, Xinjiang Medical University, Urumqi, Xinjiang, China.
Papers in Europe PMC - 02Chen Y8 papers · 2026
Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, P.R.C.
Papers in Europe PMC - 03Liu Y8 papers · 2026
Department of Pathology , Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Papers in Europe PMC - 04Wang Y7 papers · 2026
Department of Cardiology, No. 945 Hospital of the PLA Joint Logistics Support Force, Yaan, 625000, Sichuan, China.
Papers in Europe PMC - 05Wang H6 papers · 2025
Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering and Cancer Institute of the First Affiliated Hospital, Hainan Medical University, Haikou, China.
Papers in Europe PMC - 06Wang J6 papers · 2026
The Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China.
Papers in Europe PMC - 07Yang Y6 papers · 2025
Department of Thoracic Surgery, Affiliated Hospital of Southwest JiaotongUniversity, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Papers in Europe PMC - 08Zhang X6 papers · 2026
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Papers in Europe PMC - 09Chen J5 papers · 2025
Department of Breast Medicine, Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan 528000, China.
Papers in Europe PMC - 10Chen X5 papers · 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
5
interventional trials for this specific condition
5 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 2,551 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
5 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 89.2th percentile).
low confidence · 89.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
5 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07284186·RECRUITING·First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma · Gastric Adenocarcinoma · Gastric Squamous Cell Carcinoma · Gastroesophageal Junction (GEJ) Adenocarcinoma·Matched via name phrase
Broader category: squamous cell carcinoma
2,551
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 61 · after dedupe 61 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 61 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (61)
- isrctn·ISRCTN12291894·Recruiting·Investigating strength training exercise prior to surgery in patients with gullet and stomach cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12055450·Recruiting·Respiratory-swallow training in head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69516953·Not yet recruiting·Protection against invasive non-typhoidal salmonella disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42379352·No longer recruiting·Quantifying and modifying ultra-processed food intake in the management of functional dyspepsia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78284158·No longer recruiting·Heated intraperitoneal chemotherapy for the treatment of primary ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65855590·Recruiting·Bivalent vaccination against Salmonella Typhi and Paratyphi A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15046526·Recruiting·A platform trial for patients with relapsed malignant mesothelioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13625876·No longer recruiting·A study to assess in-the-moment product liking of a heating device with two variants of an alternative non-tobacco, nicotine-containing consumable in healthy adult heated tobacco product users
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12292888·No longer recruiting·(Treatments to shrink tumors before surgery, radiation or other forms of nondrug therapy) to use the investigational drug (Darovasertib) in patients with a type of cancer in the middle of the eye wall.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50098578·Recruiting·A clinical trial to investigate if proton beam therapy with chemotherapy given before surgery for patients with oesophageal cancer that has spread to the surrounding tissues, significantly reduces the severe side effects to the heart and lungs and allows immunotherapy to be started sooner after surgery when compared with standard radiotherapy and chemotherapy before surgery, and whether this delivers value to the NHS and patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14298588·No longer recruiting·A study to examine the effects of preoperative envafolimab and chemotherapy in advanced stomach and gastroesophageal junction cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11391038·No longer recruiting·Darovasertib is being used in comparison to crizotinib versus investigators' choice of treatment for negative (no specific marker) in this rare type of eye cancer which has been spread to other parts of the body, beyond the eye.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41455091·No longer recruiting·A study to evaluate the effect of highly reduced kidney function on the processing of fenebrutinib in the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46432183·No longer recruiting·A study to evaluate the effect of various degrees of reduced liver function on the processing of fenebrutinib in the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18401827·No longer recruiting·National root cause analysis to lower missed diagnoses of oesophageal and gastric cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14417629·No longer recruiting·Does having regular follow-up after surgery lead to early detection of the cancer returning, resulting in improved survival and better quality of life in patients who have had gullet or gastric cancer removal?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14903256·No longer recruiting·Study of the efficacy and safety of parsaclisib in participants with primary warm autoimmune hemolytic anemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10010669·No longer recruiting·A study to assess the effect of tiragolumab in presence of atezolizumab and bevacizumab in participants detected with lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45653542·No longer recruiting·Biologically adaptive radiotherapy for oropharyngeal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18574865·No longer recruiting·An open-label Phase Ib time-to-event continual reassessment method of dose-escalation of tolinapant (ASTX660) in combination with standard radical chemotherapy and radiotherapy in patients with cervical cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16171129·No longer recruiting·A randomised Phase II trial to assess whether niraparib is beneficial in patients with mesothelioma that has progressed and been previously treated when compared to the standard of care treatment, termed active symptom control
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63646763·No longer recruiting·A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15485902·No longer recruiting·Development of a vaccine against Salmonella Paratyphi A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10792815·No longer recruiting·A study to compare low-volume blood sampling techniques versus conventional blood collection from veins to evaluate drug concentration profiles after administration of a single dose of various study drugs in healthy subjects
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the stomach — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the stomach" OR "Squamous cell carcinoma of stomach" OR "Gastric squamous cell carcinoma" OR "gastric (stomach) squamous cell cancer" OR "stomach squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the stomach" OR "Squamous cell carcinoma of stomach" OR "Gastric squamous cell carcinoma" OR "gastric (stomach) squamous cell cancer" OR "stomach squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 5 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1035) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T15:46:13.731Z
